Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.27%
#2 MiL.k Alliance MiL.k Alliance +22.68%
#3 Biconomy Biconomy +20.40%
#4 The Black Bull The Black Bull +17.73%
#5 THORChain THORChain +17.53%
#6 Wrapped STX (Velar) Wrapped STX (Velar) +16.51%
#7 Tutorial Tutorial +13.02%
#8 THORChain Yield THORChain Yield +12.99%
#9 XPIN Network XPIN Network +12.89%
#10 MetaDAO MetaDAO +12.86%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Clasificación en acciones #5115
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Precio por acción
$58.70
Última sincronización: 2024-01-23
Capitalización bursátil
$2.98B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Mirati Therapeutics, Inc. (MRTX)

Categoría

Healthcare
Historial de rendimiento por dividendo de Mirati Therapeutics, Inc. (MRTX)
Rendimiento por dividendo (TTM) de Mirati Therapeutics, Inc. (símbolo bursátil: MRTX) al 2026: 0
Rendimiento promedio por dividendo de los últimos 5 años: 0.00%
Historial de rendimiento por dividendo de Mirati Therapeutics, Inc. (MRTX) desde 2026 hasta 2026
Rendimiento por dividendo al final de cada año (TTM)
Año Rendimiento por dividendo Cambiar
Not enough data for the provided dates.
Rendimientos por dividendo (TTM) de empresas similares o competidoras
Empresa Rendimiento por dividendo País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.12%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH